TrialBMC pharmacology & toxicology2018

A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.

Melissa Palmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.